FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
about
Treatment of Metastatic Colorectal Cancer: Standard of Care and Future PerspectivesGenomic diversity of colorectal cancer: Changing landscape and emerging targetsNeurokinin-1 receptor antagonists as antitumor drugs in gastrointestinal cancer: A new approachCurrent targeted therapies in the treatment of advanced colorectal cancer: a reviewMolecular Subtypes and Personalized Therapy in Metastatic Colorectal CancerAdvances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal CancerMolecular testing to optimize therapeutic decision making in advanced colorectal cancerAdvances in targeted and immunobased therapies for colorectal cancer in the genomic eraClinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancerProfile of panitumumab as first-line treatment in patients with wild-type KRAS metastatic colorectal cancerAdjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysisTropomyosin-related kinase B/brain derived-neurotrophic factor signaling pathway as a potential therapeutic target for colorectal cancerTherapeutic strategy in unresectable metastatic colorectal cancer: an updated reviewIrinotecan, a key chemotherapeutic drug for metastatic colorectal cancerTreatment-related gastrointestinal toxicities and advanced colorectal or pancreatic cancer: A critical updateBiomarkers of Angiogenesis in Colorectal CancerA Systematic Review and Network Meta-Analysis of Biologic Agents in the First Line Setting for Advanced Colorectal CancerTreatment of peritoneal metastases from colorectal cancerIntrahepatic therapy for liver-dominant metastatic colorectal cancerMolecular phenotypes of colorectal cancer and potential clinical applicationsTiming and extent of response in colorectal cancer: critical review of current data and implication for future trialsAnti-angiogenic agents in metastatic colorectal cancerManagement of colorectal cancerAssociation between Polymorphisms in Vascular Endothelial Growth Factor Gene and Response to Chemotherapies in Colorectal Cancer: A Meta-AnalysisTreatment of metastatic colorectal cancer: focus on panitumumabCetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival.Beyond RAS and BRAF: a target rich disease that is ripe for pickingFIRST BRAZILIAN CONSENSUS ON MULTIMODAL TREATMENT OF COLORECTAL LIVER METASTASES. MODULE 1: PRE-TREATMENT EVALUATIONTherapeutic options for peritoneal metastasis arising from colorectal cancerRelationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancerRole of targeted therapy in metastatic colorectal cancerTherapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidenceMechanisms of resistance to anti-EGFR therapy in colorectal cancerRAS and BRAF in metastatic colorectal cancer managementMechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancerPanitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS StatusEpidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancerIs conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classificationExtended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkersTranslating genomic profiling to gastrointestinal cancer treatment.
P2860
Q26738801-EDF450D7-0E23-47F1-B0B4-D9CA09372439Q26739052-34B0C327-D55A-4E4C-A965-86105A6D1A82Q26739681-7423E7C9-99A4-498C-9EB4-42B4320B97E3Q26740067-10BE6CA8-4DEA-46F5-8F67-BCB584285F4CQ26747329-C9ED6D48-8119-4893-AC1C-69D7E70084E4Q26748924-AF9BC85D-3196-4F21-AC3A-7E2F5D13920DQ26749012-0E016DEB-41D4-4E61-BC27-2703B8258200Q26751344-3CE0BC3F-A08D-4C7D-BCC8-328AC2A7F7B6Q26769958-D83E3FB1-00EE-4520-97EC-E20FDF02AE55Q26771952-55FFEB22-9BDC-433E-9164-5080B5442CEFQ26774704-4B6CCCC3-977C-4120-8B05-69EE1134E3C9Q26774713-B0D29403-AE2F-428D-9993-D48A1C9D633FQ26775522-E864A422-0BED-4732-ABF5-83DC08F193DDQ26775949-3FF20F9B-4FB8-42BD-B725-67D397F8B879Q26778004-B8BC6256-F90C-4280-9A26-D441FF440433Q26778891-2C3F7551-F414-407E-BC43-1988391C4BABQ26782245-E71C3A47-F907-46F9-971F-F99127A7033AQ26783662-917954CB-8775-41C4-A992-707484708923Q26784221-B1EACF88-4125-4C3B-8EAA-60A5C095E5FFQ26785725-B240A76D-576A-4536-8437-A2C65BD8ECE7Q26797292-DB3DB08E-12DD-410E-AC52-5C97BF98DC15Q26801911-DFBBFBDC-77A3-46D3-A21A-26FC2138C2AEQ26823550-7AEFEBCC-3315-4FE6-B3F9-64D377C7BBADQ26862559-504E4752-2877-43D8-86F0-645FB3B44423Q27022954-C7783C8F-8BAD-4FB7-A576-E2EDC84B6154Q27853284-3FD63B2E-8E38-40AC-BA5E-5EBADE5D2A36Q28066095-DF26A41B-274E-4B65-B404-3982554678EFQ28066171-9ABA13A0-5DE6-47AA-8E23-0F17561CDBA9Q28067123-D151B85C-4385-432D-B8C4-7F4114834B52Q28068654-08E7F10B-12B3-42E5-9023-4A79C168111FQ28068817-77B9D570-9578-411A-A7DE-EDC74453E6CFQ28071772-B9B0EDEC-4845-4BD1-AD5E-76E181F22485Q28074073-BE00C8F0-6D2E-44A3-9895-552A3808AD01Q28074175-16E14565-3D5D-45D9-B844-5B27C7D462BCQ28076490-730968C4-FC0C-4216-A05D-E664210EA13FQ28082816-9A8A3FA8-89AD-4FD5-91CC-E7ED34C4CF0DQ28084216-503A965C-B687-4106-96D8-375F10A7E662Q28084888-C36036EA-B0B4-454F-9E7D-BDE88C8C3B4AQ28087333-5C30A987-7909-420B-87FF-0B738D1A4C24Q30239109-F5672AAD-B278-4320-82CA-3AC6E934C734
P2860
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
FOLFIRI plus cetuximab versus ...... ed, open-label, phase 3 trial.
@ast
FOLFIRI plus cetuximab versus ...... ed, open-label, phase 3 trial.
@en
FOLFIRI plus cetuximab versus ...... ed, open-label, phase 3 trial.
@nl
type
label
FOLFIRI plus cetuximab versus ...... ed, open-label, phase 3 trial.
@ast
FOLFIRI plus cetuximab versus ...... ed, open-label, phase 3 trial.
@en
FOLFIRI plus cetuximab versus ...... ed, open-label, phase 3 trial.
@nl
prefLabel
FOLFIRI plus cetuximab versus ...... ed, open-label, phase 3 trial.
@ast
FOLFIRI plus cetuximab versus ...... ed, open-label, phase 3 trial.
@en
FOLFIRI plus cetuximab versus ...... ed, open-label, phase 3 trial.
@nl
P2093
P921
P1433
P1476
FOLFIRI plus cetuximab versus ...... ed, open-label, phase 3 trial.
@en
P2093
Alexander Kiani
Andreas Jung
Andreas Rost
Christian Lerchenmüller
Christoph Kahl
Dominik P Modest
Frank Kullmann
Gernot Seipelt
Hartmut Link
Heinz-Gert Höffkes
P304
P356
10.1016/S1470-2045(14)70330-4
P577
2014-07-31T00:00:00Z